Abstract
The most common treatments for infectious diseases target the invading pathogen. The efficacy of such an approach may, however, be countered by the possibility of the development of resistance to a pharmacophore, through mutation(s) in pathogen molecules required for activity. Given the fact that pathogens exploit host factors in order to grow in an otherwise hostile environment, one possible way to circumvent the emergence of resistance is to develop drugs that target non-essential host factors hijacked by the pathogen, rather than the pathogen’s own molecules. Such solutions are already being developed for various viral and bacterial pathogens, but much less has been achieved with infections caused by protozoan parasites, as is the case of Plasmodium. Here, we highlight recent progress in host target-based anti-viral and anti-bacterial approaches and discuss possible host targets that may be used for anti-malarial interventions. Host molecules that play a role during either the liver or the blood stage of Plasmodium infection are outlined and their potential merits as anti-malarial targets are discussed.
Keywords: Malaria, Plasmodium, host factors, host targets, hepatitis C virus, liver-stage, blood-stage, drug resistance
Current Pharmaceutical Design
Title:Targeting Host Factors to Circumvent Anti-Malarial Drug Resistance
Volume: 19 Issue: 2
Author(s): Miguel Prudencio and Maria M. Mota
Affiliation:
Keywords: Malaria, Plasmodium, host factors, host targets, hepatitis C virus, liver-stage, blood-stage, drug resistance
Abstract: The most common treatments for infectious diseases target the invading pathogen. The efficacy of such an approach may, however, be countered by the possibility of the development of resistance to a pharmacophore, through mutation(s) in pathogen molecules required for activity. Given the fact that pathogens exploit host factors in order to grow in an otherwise hostile environment, one possible way to circumvent the emergence of resistance is to develop drugs that target non-essential host factors hijacked by the pathogen, rather than the pathogen’s own molecules. Such solutions are already being developed for various viral and bacterial pathogens, but much less has been achieved with infections caused by protozoan parasites, as is the case of Plasmodium. Here, we highlight recent progress in host target-based anti-viral and anti-bacterial approaches and discuss possible host targets that may be used for anti-malarial interventions. Host molecules that play a role during either the liver or the blood stage of Plasmodium infection are outlined and their potential merits as anti-malarial targets are discussed.
Export Options
About this article
Cite this article as:
Prudencio Miguel and M. Mota Maria, Targeting Host Factors to Circumvent Anti-Malarial Drug Resistance, Current Pharmaceutical Design 2013; 19 (2) . https://dx.doi.org/10.2174/1381612811306020290
DOI https://dx.doi.org/10.2174/1381612811306020290 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nutritional Control, Gene Regulation, and Transformation of Vascular Smooth Muscle Cells in Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets Prevalence of Vertebral Fractures, Vascular Calcifications, and Mortality in Warfarin Treated Hemodialysis Patients
Current Vascular Pharmacology S-nitrosation/Denitrosation in Cardiovascular Pathologies: Facts and Concepts for the Rational Design of S-nitrosothiols
Current Pharmaceutical Design Neuropsychiatric Involvement in Systemic Lupus Erythematosus:Current Therapeutic Approach
Current Pharmaceutical Design Chymase Inhibitors
Current Pharmaceutical Design Biomarkers Associated with Bleeding Risk in the Setting of Atrial Fibrillation
Current Medicinal Chemistry Immunossupressant and Organ Transplantation: Immunophilins Targeting Agent and Alternative Therapies
Current Medicinal Chemistry Patent Selections
Recent Patents on Cardiovascular Drug Discovery Multivariate Optimization Model in a Partial Least Squares-1 Method for Simultaneous Determination of Dorzolamide Hydrochloride and Timolol Maleate in Eye Drops
Current Pharmaceutical Analysis Cardiovascular Complications in Inflammatory Bowel Disease
Current Drug Targets SUBJECT INDEX TO VOLUME 4 Current Organic Chemistry
Current Organic Chemistry Organizational Impact of the Introduction of a New Portable Syringe Pump for Iloprost Therapy in Italian Hospital Settings
Current Drug Therapy Carotid Endarterectomy and Carotid Artery Stenting Lead to Improved Cognitive Performance in Patients with Severe Carotid Artery Stenosis
Current Neurovascular Research Low Molecular Weight and Oligomeric Chitosans and Their Bioactivities
Current Topics in Medicinal Chemistry Downstream Processing of Bioactive Compounds from Milk and Whey
Current Biochemical Engineering (Discontinued) Endothelin and Oxidative Stress in the Vascular System
Current Vascular Pharmacology Diabetic Papillopathy: Current and New Treatment Options
Current Diabetes Reviews Cardiovascular Effects of Flavonoids
Current Medicinal Chemistry Changes in Lung Function After Compressed Air Diving
Current Respiratory Medicine Reviews Common Variants for Heart Failure
Current Genomics